SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (SNWV) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for SANUWAVE Health, Inc. (SNWV), featuring income statements, balance sheets, and cash flow data.
SANUWAVE Health, Inc. (SNWV) Income Statement & Financial Overview
View the income breakdown for SANUWAVE Health, Inc. SNWV across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $9.34M | $10.33M | $9.36M | $7.16M |
| Cost of Revenue | $1.96M | $2.29M | $2.29M | $1.92M |
| Gross Profit | $7.38M | $8.04M | $7.07M | $5.24M |
| Gross Profit Ratio | $0.79 | $0.78 | $0.76 | $0.73 |
| R&D Expenses | $208000.00 | $154000.00 | $161000.00 | $195000.00 |
| SG&A Expenses | $6.00M | $5.14M | $4.75M | $2.87M |
| Operating Expenses | $6.21M | $5.52M | $5.11M | $3.07M |
| Total Costs & Expenses | $8.16M | $7.80M | $7.41M | $5.17M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | -$1.85M | $2.63M | $3.66M | $3.78M |
| Depreciation & Amortization | $192000.00 | $53000.00 | $256000.00 | $262000.00 |
| EBITDA | $1.18M | -$9.68M | $2.16M | $2.25M |
| EBITDA Ratio | $0.13 | -$0.94 | $0.23 | $0.31 |
| Operating Income | $986000.00 | $2.52M | $1.95M | $1.99M |
| Operating Income Ratio | $0.11 | $0.24 | $0.21 | $0.28 |
| Other Income/Expenses (Net) | -$6.66M | -$15.24M | -$22.61M | $4.57M |
| Income Before Tax | -$5.68M | -$12.72M | -$20.66M | $6.56M |
| Income Before Tax Ratio | -$0.61 | -$1.23 | -$2.21 | $0.92 |
| Income Tax Expense | $0.00 | $27000.00 | $0.00 | $0.00 |
| Net Income | -$5.68M | -$12.75M | -$20.66M | $6.56M |
| Net Income Ratio | -$0.61 | -$1.23 | -$2.21 | $0.92 |
| EPS | -$0.66 | -$1.49 | -$6.49 | $3.75 |
| Diluted EPS | -$0.66 | -$1.49 | -$6.49 | $1.77 |
| Weighted Avg Shares Outstanding | $8.55M | $8.54M | $3.19M | $3.15M |
| Weighted Avg Shares Outstanding (Diluted) | $8.55M | $8.54M | $3.19M | $3.70M |
Over the last four quarters, SANUWAVE Health, Inc. achieved steady financial progress, growing revenue from $7.16M in Q2 2024 to $9.34M in Q1 2025. Gross profit stayed firm with margins at 79% in Q1 2025 versus 73% in Q2 2024. Operating income totaled $986000.00 in Q1 2025, maintaining a 11% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $1.18M. Net income rose to -$5.68M, with EPS at -$0.66. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan